Johnson & Johnson (NYSE:JNJ) Shares Sold by J. W. Coons Advisors LLC

J. W. Coons Advisors LLC lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 7.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 23,117 shares of the company’s stock after selling 1,802 shares during the quarter. Johnson & Johnson comprises about 1.0% of J. W. Coons Advisors LLC’s investment portfolio, making the stock its 26th biggest holding. J. W. Coons Advisors LLC’s holdings in Johnson & Johnson were worth $3,834,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. WealthTrak Capital Management LLC acquired a new position in Johnson & Johnson in the 4th quarter worth approximately $26,000. Conquis Financial LLC acquired a new position in Johnson & Johnson in the 4th quarter worth approximately $33,000. Bernard Wealth Management Corp. acquired a new position in Johnson & Johnson in the 4th quarter worth approximately $36,000. Highline Wealth Partners LLC boosted its stake in Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after purchasing an additional 86 shares during the period. Finally, von Borstel & Associates Inc. acquired a new position in Johnson & Johnson in the 1st quarter worth approximately $49,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 2.2%

Shares of NYSE:JNJ opened at $167.90 on Wednesday. The firm has a market cap of $403.99 billion, a price-to-earnings ratio of 17.96, a PEG ratio of 2.09 and a beta of 0.41. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company’s fifty day simple moving average is $154.29 and its 200 day simple moving average is $155.12. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. The business had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter last year, the firm earned $2.82 earnings per share. The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. As a group, research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 3.10%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson’s payout ratio is 55.61%.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on JNJ shares. Sanford C. Bernstein reissued a “market perform” rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. The Goldman Sachs Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Benchmark raised shares of Johnson & Johnson to a “strong-buy” rating in a research note on Thursday, April 24th. Raymond James Financial reduced their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research note on Monday, April 14th. Finally, Guggenheim lifted their price objective on shares of Johnson & Johnson from $164.00 to $167.00 and gave the company a “neutral” rating in a research note on Thursday, July 17th. Eleven research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $172.87.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.